KPV 10 mg + GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
The studies behind this compound did not test timing or food state as variables, so we are not going to invent a rule. Pick a time you can keep to consistently.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 1.6 mg | daily | 0.06 mL | 6 u | 14 | 22.4 mg |
| Weeks 3–4 | 3.2 mg | daily | 0.12 mL | 12 u | 14 | 44.8 mg |
| Week 5 onward per 4 weeks from here on |
4.8 mg | daily | 0.18 mL | 18 u | 28 | 134.4 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Low reported | 1.6 mg | 1× daily | 0.06 mL | 6 u | 50 doses |
| Standard | 3.2 mg | 1× daily | 0.12 mL | 12 u | 25 doses |
| Upper reported | 4.8 mg | 1× daily | 0.18 mL | 18 u | 16 doses |
The GLOW combination with KPV added. Same fixed-ratio constraint applies, with a fourth component narrowing the titration window further.
Buy KLOW BlendPaid affiliate links.
Adding 3 mL of bacteriostatic water to a 80 mg vial gives 26.7 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for KLOW Blend run from 1.6 mg to 4.8 mg, typically 1× daily.6 mg to 4.8 mg, typically 1× daily.6 mg to 4.8 mg, typically 1× daily. This site lists each figure with the source it came from rather than giving a single recommended number.
At 26.7 mg/mL, a 1.6 mg dose is 6 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 50 doses.
KLOW Blend is graded preclinical. Laboratory and animal data only. No human dosing trials have been published. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
KLOW is GLOW with KPV added. The other three components and their amounts are unchanged — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg — and KPV 10 mg is layered on top, taking the vial from 70 mg to 80 mg.
KPV is the C-terminal tripeptide of alpha-MSH and is studied for anti-inflammatory activity, particularly in gut and skin models. It is the single reason to choose KLOW over GLOW. If inflammation is not part of what you are looking at, the extra compound is the only difference you are paying for.
Need this on one page to print, screenshot or send?
Make a dose card →Side-by-side with the compounds it is most often weighed against — doses, evidence tier and how each is mixed.
Compounds in the same class, or browse the full catalogue.
An equal-parts repair and anti-inflammatory pairing — 10 mg of each in a 20 mg vial, so every dose splits evenly down the middle a…
A GHRH analogue paired with a selective ghrelin receptor agonist — the pairing rationale is that the two receptors act synergistic…
Every compound compared in one table: dose range, how often, half-life and evidence tier.